Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.
about
Laboratory use of hepcidin in renal transplant recipientsFavorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathwayInfluence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.Simultaneous determination of mycophenolic acid and its glucuronide and glycoside derivatives in canine and feline plasma by UHPLC-UV.Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells.Current pharmacotherapy for the treatment of crescentic glomerulonephritis.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?A four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study.Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation.Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?What is the intrapatient variability of mycophenolic acid trough levels?Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials NetworkPharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.Acute humoral rejection in pediatric renal transplant recipients receiving steroid minimization immunosuppression.Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil.Limited sampling strategy of mycophenolic acid in adult kidney transplant recipients: influence of the post-transplant period and the pharmacokinetic profile.Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus-based immunosuppressive regimen.C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.Usefulness of mycophenolic acid monitoring with PETINIA for prediction of adverse events in kidney transplant recipients.Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients
P2860
Q26765316-D3EEDCF1-F26D-4B5F-9F4B-80C342FADD7EQ33423743-88477A15-BF9E-44C2-8B1E-AC2537FBAA1BQ33764989-5D86DC7A-4444-49EE-9B36-FA66B59EF3DCQ34077012-26360127-8866-4D13-B00F-6222EB7A4C4FQ35619332-4E1E737B-ECF7-4F46-B40C-AFAD49B95024Q36266188-965C2F90-2AF9-4C25-A9D9-86191B4695C9Q36420758-52F5235C-4B50-4E13-A4DA-3D4BD61E8744Q36623061-AF04BBCB-D0C8-42CA-A12F-27DA735FECDEQ36777485-D4B9A916-DED4-4D9B-B932-7A2819D60528Q36788423-C20933E0-E65D-4CEE-8575-4D58196BC269Q36912373-05CF343B-29E9-4255-B894-A3CABCD11B54Q37013588-1ABF4017-13F3-4401-8290-0F3614905B65Q37112472-E5087949-1528-4178-AA14-C96BA8975938Q38087925-AB849526-2D0E-43CC-9F55-E880A4B602FBQ38170321-E90F950C-2C7F-4B14-A5D8-6A23A16E4B0FQ40707992-08EB5CD9-2A23-4512-AF31-8127E0AB54BEQ42149848-8B69FCA1-8B90-4254-A261-4B394E86B204Q42848628-09FED1EA-C896-4404-8134-65FD47DF203CQ44534960-1C198F2E-4336-47F9-9C86-43B8F9623D12Q44600058-0B8BE0C0-BBA9-4E2A-918E-7369B516524AQ45729560-28E2FAEA-55FF-48E2-B418-B8005A785061Q46703423-7BC0E964-513A-4214-95D3-0F2CCD133FBDQ46959473-C39F9E3C-1CB7-42A3-96E0-3A1D1F1378B6Q47318170-5131FFA8-3955-4390-83D0-7763FC29A279Q50691259-3B6A4A58-E656-44FD-BF1A-0B36C1886C87Q58785681-92B843F1-1470-4AB6-97D0-A0EE7763BAC3
P2860
Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Mycophenolic acid 12-h trough ...... acute rejection and toxicity.
@ast
Mycophenolic acid 12-h trough ...... acute rejection and toxicity.
@en
type
label
Mycophenolic acid 12-h trough ...... acute rejection and toxicity.
@ast
Mycophenolic acid 12-h trough ...... acute rejection and toxicity.
@en
prefLabel
Mycophenolic acid 12-h trough ...... acute rejection and toxicity.
@ast
Mycophenolic acid 12-h trough ...... acute rejection and toxicity.
@en
P2093
P2860
P1476
Mycophenolic acid 12-h trough ...... acute rejection and toxicity.
@en
P2093
Griffith M
Loucaidou M
P2860
P304
P356
10.1111/J.1600-6143.2005.01151.X
P407
P577
2006-01-01T00:00:00Z